Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
Direct comparison studies of the tiotropium HandiHaler® 18 µg and Respimat® 5 µg formulations
have been limited to 4-week crossover studies. Therefore, prospective data from a trial of
adequate size and duration is required to establish that compared to tiotropium HandiHaler®,
tiotropium Respimat® will have (a) similar effects on safety and (b) similar or superior
effects on exacerbations.